<DOC>
	<DOC>NCT02556762</DOC>
	<brief_summary>This randomized phase III trial is to compare simultaneous modulated accelerated boost with standard dose radiotherapy given together with chemotherapy in treating patients with esophageal squamous cell carcinoma.</brief_summary>
	<brief_title>Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologic proof of primary squamous cell carcinoma of the esophagus. Primary disease at cervical, upper or middle thoracic esophagus T14, N any, M0 (except supraclavicular lymph node). Age≥18 &amp; ≤75. ECOG score 02. Platelets ≥ 150,000, Hgb ≥ 10 gm%, ANC ≥ 1500, serum creatinine ≤ 1.5 mg/dl. Adequate liver function. Patients with prior malignancy are eligible if diseasefree ≥ 5 years. No prior chest radiotherapy, systemic chemotherapy or major esophageal surgery. Signed studyspecific informed consent form prior to study entry. Patients with tracheoesophageal fistula. Patients with invasion into mucosa of trachea or major bronchi. Patients with uncontrolled serious medical or mental illnesses. Prior RT that would result in overlap of planned RT fields. Pregnancy or women of childbearing potential and men who are sexually active Women who are breastfeeding a baby.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Simultaneous modulated accelerated boost</keyword>
	<keyword>Standard dose radiotherapy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Survival</keyword>
</DOC>